Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds.
Liu, J., Dyer, D., Cheng, J., Wang, J., Wang, S., Yang, Z., Wang, X., Hu, W.(2013) Parasit Vectors 6: 162-162
- PubMed: 23734964 
- DOI: https://doi.org/10.1186/1756-3305-6-162
- Primary Citation of Related Structures:  
4HBK - PubMed Abstract: 
Schistosomiasis is a neglected tropical disease with high morbidity and mortality in the world. Currently, the treatment of this disease depends almost exclusively on praziquantel (PZQ); however, the emergence of drug resistance to PZQ in schistosomes makes the development of novel drugs an urgent task. Aldose reductase (AR), an important component that may be involved in the schistosome antioxidant defense system, is predicted as a potential drug target.
Organizational Affiliation: 
Key Laboratory of Parasite and Vector Biology of MOH, Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, 207 Rui-Jin Road II, Shanghai, China.